Longevity Interventions: What Actually Works
Photo: cottonbro studio / Pexels
The global longevity market will exceed $600 billion by 2028, fueled by a flood of supplements, biohacking protocols, and celebrity-endorsed interventions. Most of it is noise. A small but meaningful set of interventions, however, is supported by rigorous evidence — and understanding the difference between tiers of evidence may be the most valuable thing you can do for your long-term health.
Educational content, not medical advice. Talk to your doctor before changing any medication, treatment, or routine. Information here reflects current research but every person's situation differs.
This review organizes longevity interventions into four evidence tiers, drawing on landmark trials, meta-analyses, and the NIA Interventions Testing Program (ITP), which systematically tests compounds for lifespan extension in genetically heterogeneous mice.
To understand why these interventions work at a cellular level, see our deep dive on aging biology and longevity science.
Evidence Tiers at a Glance
| Intervention | Tier | Evidence Strength | Key Source |
|---|---|---|---|
| Cardiorespiratory fitness (VO2max) | 1 | ★★★★★ | Mandsager 2018, JAMA Network Open |
| Not smoking | 1 | ★★★★★ | CDC, multiple cohorts |
| Sleep 7–9 hours | 1 | ★★★★☆ | Walker 2017; multiple prospective |
| Healthy BMI / weight | 1 | ★★★★☆ | NEJM, Global BMI Mortality Collaboration |
| Social connection | 1 | ★★★★☆ | Holt-Lunstad 2015, PLOS Medicine |
| Mediterranean diet | 2 | ★★★☆☆ | PREDIMED, NEJM 2013 |
| Avoiding ultra-processed food | 2 | ★★★☆☆ | Monteiro NOVA; multiple cohorts |
| Sauna (4–7x/week) | 2 | ★★★☆☆ | Laukkanen 2018, BMC Medicine |
| Cold exposure | 2 | ★★☆☆☆ | Limited human RCTs |
| Hearing aids (dementia risk) | 2 | ★★★☆☆ | Lancet Commission 2024 |
| Metformin (TAME trial) | 3 | ★★☆☆☆ | Barzilai — trial in progress |
| NMN / NR (NAD+ precursors) | 3 | ★★☆☆☆ | Brenner 2023 review |
| Rapamycin | 3 | ★★☆☆☆ | Harrison 2009 Nature; human data sparse |
| Senolytics (D+Q) | 3 | ★★☆☆☆ | Mayo Clinic pilot trials |
| Resveratrol | 4 | ★☆☆☆☆ | Conflicting; Sirtris controversy |
| Most supplement stacks | 4 | ★☆☆☆☆ | No RCT evidence for lifespan |
| Cryonics | 4 | ★☆☆☆☆ | No scientific basis currently |
Tier 1: Strong Evidence
Exercise — The Single Best Longevity Intervention
No drug, supplement, or biohack comes close to exercise for extending healthy life. A landmark 2018 study by Mandsager and colleagues, published in JAMA Network Open, tracked 122,007 patients who underwent exercise treadmill testing. The findings were stark: low cardiorespiratory fitness was associated with a higher mortality risk than smoking, hypertension, or diabetes. Fitness was the single strongest predictor of all-cause mortality in the dataset.
VO2max — the maximum rate at which your body can consume oxygen — is the key metric. Compared to "elite" fitness levels, being in the bottom 25% ("low" fitness) carried a relative risk of death roughly comparable to having established heart disease.
What the evidence supports:
- Zone 2 cardio (conversational-pace sustained effort, ~60–70% max heart rate): 150–200 minutes per week builds mitochondrial density and metabolic flexibility
- Resistance training: muscle mass is an independent predictor of longevity; sarcopenia accelerates mortality risk in older adults
- VO2max training: 1–2 sessions per week of high-intensity intervals (e.g., 4×4 minutes at 90–95% max heart rate) meaningfully raises VO2max over 8–12 weeks
Peter Attia's "Centenarian Decathlon" framework is one of the most practically useful approaches to exercise for longevity. The idea: identify the physical activities you want to perform at age 90, then train backwards from those goals now. If you want to carry groceries, climb stairs, and pick up grandchildren at 90, you need substantially more strength and aerobic capacity today than those tasks require — because you will lose roughly 1% of muscle mass and 10% of VO2max per decade after age 30. This reframes exercise not as lifespan extension per se, but as healthspan preservation — the quality of years, not just the quantity.
Not Smoking
Smoking remains one of the most well-documented drivers of premature death. Long-term smokers lose approximately 10 years of life expectancy compared to never-smokers. Quitting before age 40 recovers roughly 90% of that lost expectancy. The evidence here is overwhelming, consistent across every major epidemiological cohort, and causal.
Sleep 7–9 Hours
Sleep is one of the most underrated longevity variables. Both short sleep (under 6 hours) and long sleep (over 9 hours) are associated with elevated all-cause mortality risk in prospective studies. The relationship is J-shaped, with 7–8 hours representing the lowest-risk range.
Mechanistically, sleep is when the glymphatic system clears amyloid-beta and tau from the brain — misfolded proteins implicated in Alzheimer's disease. Chronic sleep restriction also elevates cortisol, impairs glucose metabolism, suppresses immune function, and disrupts growth hormone secretion.
Our article on sleep science and why we sleep covers the mechanisms in depth.
Healthy Body Weight
Excess adiposity — particularly visceral fat — drives chronic low-grade inflammation, insulin resistance, hypertension, and dyslipidemia. A 2016 meta-analysis in The Lancet using data from 239 prospective studies found a linear relationship between BMI above 25 and all-cause mortality. The optimal BMI range in most analyses sits between 20 and 25, though the relationship varies by age and ethnicity.
Social Connection
One of the most surprising findings in longevity research is the magnitude of social isolation's effect on mortality. A 2015 meta-analysis by Holt-Lunstad and colleagues in PLOS Medicine, covering 148 studies and over 300,000 participants, found that adequate social relationships were associated with a 50% greater likelihood of survival. The effect size was comparable to quitting smoking and substantially larger than physical inactivity or obesity.
Loneliness appears to work through multiple pathways: elevated cortisol and inflammatory cytokines, impaired sleep, reduced motivation for health behaviors, and direct effects on cardiovascular regulation.
Tier 2: Moderate Evidence
Mediterranean Diet
The PREDIMED trial (New England Journal of Medicine, 2013) is the largest randomized trial of a dietary pattern for cardiovascular outcomes. Roughly 7,500 high-risk Spanish adults were assigned to a Mediterranean diet supplemented with either olive oil or nuts, or a control low-fat diet. The Mediterranean diet groups showed a ~30% relative reduction in major cardiovascular events over ~5 years.
Limitations: the trial was retracted and republished due to randomization irregularities, but effect sizes were essentially unchanged after reanalysis. Overall diet quality, not any single nutrient, appears to be the key variable.
Avoiding Ultra-Processed Foods
The NOVA classification system (Monteiro et al.) defines ultra-processed foods as industrial formulations containing ingredients rarely used in home cooking — emulsifiers, artificial colors, flavor enhancers. Multiple large prospective cohort studies find that high ultra-processed food intake is associated with elevated risk of cardiovascular disease, type 2 diabetes, and all-cause mortality, even after adjusting for total calories and nutrient quality. The mechanisms likely include food additive effects on the gut microbiome, disrupted satiety signaling, and high glycemic load.
The gut microbiome is a key intermediary here — see our piece on the human microbiome and gut-brain axis.
Sauna Use
Finnish researcher Jari Laukkanen has produced some of the most compelling observational data on sauna use. A 2018 study in BMC Medicine found that men who used the sauna 4–7 times per week had a 40% lower risk of all-cause mortality compared to once-weekly users. Cardiovascular and sudden cardiac death risk were both significantly reduced.
The mechanisms are plausible: repeated sauna exposure induces heat shock proteins, reduces arterial stiffness, lowers blood pressure, and appears to mimic some cardiovascular adaptations of moderate aerobic exercise. Whether these are independent effects or confounded by the healthy behaviors of frequent sauna users remains debated. Still, the dose-response relationship is consistent across multiple Finnish cohort studies.
Cold Exposure
Regular cold water immersion and cold showers have gained mainstream attention, but the human evidence for longevity benefits is much weaker than the sauna data. Most trials are short-term and focus on inflammation markers, mood, or subjective recovery rather than hard outcomes. Cold exposure does appear to activate brown adipose tissue and increase norepinephrine, which may have metabolic benefits. The evidence does not yet support strong claims about lifespan extension.
Hearing Aids and Dementia Risk
The 2024 Lancet Commission on Dementia Prevention identified hearing loss as one of the largest modifiable risk factors for dementia — accounting for an estimated 8% of dementia cases. A 2023 RCT published in The Lancet found that hearing intervention reduced cognitive decline by 48% over 3 years in high-risk older adults. Treating hearing loss is a rare, underutilized, and highly practical dementia prevention strategy.
Tier 3: Emerging Interventions
Metformin — TAME Trial
Metformin is a cheap, safe diabetes drug with a surprisingly robust longevity profile in observational data. Diabetics taking metformin sometimes outlive matched non-diabetic controls — a striking finding. The drug activates AMPK, mimics caloric restriction signaling, and reduces mTOR activity.
The Targeting Aging with Metformin (TAME) trial, led by Nir Barzilai, is the first clinical trial specifically designed to test an intervention against biological aging as a primary endpoint. Results are expected mid-decade. Until RCT evidence arrives, metformin remains promising but unproven for non-diabetic longevity use.
NMN and NR — NAD+ Precursors
Nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN) are precursors to NAD+, a coenzyme that declines with age and is central to cellular energy metabolism, DNA repair, and sirtuin activity. Mouse studies are dramatic — NAD+ restoration reverses some aging phenotypes. Human trials are far less impressive.
A comprehensive 2023 review by Charles Brenner (Nature Metabolism) concluded that while NR safely raises blood NAD+ levels in humans, there is no RCT evidence that this translates to meaningful health or longevity outcomes. The mouse-to-human translation problem is real: mice have far shorter lifespans and different NAD+ metabolism. The supplement industry has run far ahead of the science on this one.
Rapamycin
Rapamycin (sirolimus) inhibits mTOR, a central regulator of cellular growth and autophagy. It is the most reproducible lifespan-extending drug in mice, extending median lifespan by 10–25% even when started in middle-aged animals (Harrison et al., Nature, 2009). The NIA ITP has replicated this finding.
In humans, rapamycin is used as an immunosuppressant in organ transplant patients — which limits enthusiasm for broad use. Some longevity physicians are experimenting with low-dose intermittent protocols, but no RCT has tested rapamycin for aging endpoints in healthy humans. Long-term safety data does not exist for this use case. This is a genuinely exciting target, but the evidence gap between mice and humans remains wide.
Senolytics — Dasatinib + Quercetin
Senescent cells accumulate with age and secrete pro-inflammatory molecules (the SASP — senescence-associated secretory phenotype). Senolytics are drugs designed to selectively kill senescent cells. The combination of dasatinib (a cancer drug) and quercetin (a plant flavonoid) has cleared senescent cells in mouse models with impressive results.
Human pilot trials from the Mayo Clinic have shown that D+Q can reduce senescent cell burden in humans, and early trials in specific diseases (idiopathic pulmonary fibrosis, diabetic kidney disease) show signals. Whether periodic senolytic treatment extends healthy lifespan in otherwise healthy humans is unknown. Larger trials are underway.
Tier 4: Overhyped
Resveratrol
Resveratrol — a polyphenol in red wine — was the longevity darling of the 2000s, largely due to David Sinclair's work suggesting it activated sirtuins. GlaxoSmithKline acquired Sinclair's company Sirtris for $720 million in 2008. The subsequent RCTs were deeply disappointing: resveratrol did not extend lifespan in mice at standard doses, did not improve cardiovascular outcomes in humans, and may even blunt some exercise adaptations. The Sirtris drug pipeline failed. The science moved on. The supplement industry has not.
Most Supplement Stacks
The vast majority of marketed longevity supplements — collagen, CoQ10, telomere supplements, anti-aging blends — lack any RCT evidence for lifespan or healthspan outcomes in humans. Some have reasonable biological rationale. None have demonstrated efficacy in properly powered trials.
Cryonics and Extreme Protocols
Cryonics — preserving the body at death in the hope of future revival — has no scientific evidence base. Current vitrification techniques cause cellular damage that no plausible future technology has demonstrated the ability to reverse.
Bryan Johnson's Blueprint protocol generates significant media attention. It involves 100+ supplements, extensive biomarker tracking, and extreme lifestyle optimization. While some individual components are evidence-based (exercise, sleep, diet quality), the specific protocol as a whole has no RCT support. Biomarker optimization is not the same as lifespan extension.
The Supercentenarian Data Problem
Research on people who live to 110+ (supercentenarians) should offer clues about the outer limits of human longevity. A 2018 Science paper by Barbi and colleagues analyzed Italian supercentenarians and found that mortality risk plateaus after age 105 — contradicting actuarial models predicting continued exponential rise. The finding was widely cited as evidence that there may be no fixed maximum human lifespan.
However, subsequent analyses raised serious questions about Italian birth record accuracy in the late 1800s. Age verification errors — people recorded as slightly older or younger than their true age — can produce statistical artifacts that mimic mortality plateau effects. The data quality issues in supercentenarian research are a genuine methodological problem. Most extreme claims about maximum human lifespan rest on shakier foundations than commonly acknowledged.
What to Actually Do
The evidence hierarchy is clear. The interventions with the strongest evidence are also the least glamorous:
- Become cardiorespiratory fit — zone 2 cardio + resistance training + periodic VO2max work
- Don't smoke
- Sleep 7–9 hours with consistent timing
- Maintain healthy body weight through diet quality and activity
- Invest in social relationships — they are as important as physical health behaviors
- Eat mostly whole foods — Mediterranean-style as a rough template
- Treat hearing loss if present
Emerging interventions (metformin, rapamycin, senolytics) may eventually prove transformative, but the evidence does not yet justify routine use outside of research contexts or clinical supervision.
The gap between what the evidence supports and what the longevity industry sells is enormous. The interventions that actually work are free or cheap. Most of what costs money and generates headlines does not.
Frequently Asked Questions
Q: What is the single most impactful longevity intervention? A: Cardiorespiratory fitness — specifically VO2max — is the strongest predictor of all-cause mortality in large prospective studies. A 2018 JAMA Network Open study of over 122,000 patients found low fitness to be a more powerful mortality risk factor than smoking, hypertension, or diabetes. Exercise is the intervention with the strongest, most consistent evidence across the longest time horizon.
Q: Does the Mediterranean diet actually extend lifespan? A: The Mediterranean diet has strong evidence for reducing cardiovascular events — the PREDIMED trial (NEJM 2013) showed roughly 30% relative risk reduction. Direct evidence for all-cause mortality reduction is more limited, but the diet pattern consistently associates with better health outcomes in large cohort studies. It's a sound dietary framework, not a magic bullet.
Q: Is NMN worth taking for longevity? A: Current evidence does not support NMN supplementation for longevity in healthy humans. While NMN safely raises blood NAD+ levels, a comprehensive 2023 review by Charles Brenner concluded there is no RCT evidence this translates to meaningful health outcomes. Mouse data is dramatic; human trial data is underwhelming. The supplement is expensive relative to its demonstrated benefit.
Q: Why is rapamycin not more widely used for longevity if it works in mice? A: Rapamycin reproducibly extends mouse lifespan — the most robust finding in the NIA Interventions Testing Program. However, it is an immunosuppressant used in organ transplant patients, and its long-term safety at low intermittent doses in healthy humans is unknown. No RCT has tested it for aging in healthy people. The risk-benefit calculation is unclear without that data.
Q: Does social connection really affect longevity as much as diet and exercise? A: Yes, according to the evidence. Holt-Lunstad's 2015 PLOS Medicine meta-analysis of 148 studies found social isolation associated with a 50% reduction in survival odds — comparable in magnitude to the effect of smoking cessation, and larger than physical inactivity or obesity. Social connection appears to work through multiple biological pathways including inflammation, cortisol regulation, and sleep quality.
Q: What is the "Centenarian Decathlon" and why does it matter? A: The Centenarian Decathlon is a framework developed by physician Peter Attia that reframes longevity training around functional goals at age 90 — what physical activities do you want to perform, and what fitness level do you need now to still perform them after decades of age-related decline? It shifts focus from lifespan to healthspan and encourages building substantially more strength and aerobic capacity than current activities require, given expected future losses.
Q: Is there a maximum human lifespan? A: This remains genuinely debated. A 2018 Science paper on Italian supercentenarians suggested mortality risk plateaus after 105, implying no fixed maximum. However, subsequent analyses raised serious concerns about birth record accuracy in the dataset — age verification errors in late 19th-century records can create statistical artifacts. The data quality problems in supercentenarian research mean confident claims about maximum lifespan should be treated with skepticism.
Q: What about Bryan Johnson's Blueprint protocol? A: Bryan Johnson's protocol includes many evidence-based components — rigorous sleep tracking, exercise, whole-food diet — but the specific combination of 100+ supplements and extreme optimization has no RCT evidence as a complete protocol. Biomarker improvement does not equal lifespan extension, and optimizing dozens of markers simultaneously without controlled trials makes it impossible to attribute outcomes to any specific intervention. Individual components vary from evidence-based to speculative.
Sources
- Mandsager K et al. (2018). Association of cardiorespiratory fitness with long-term mortality among adults undergoing exercise treadmill testing. JAMA Network Open, 1(6), e183605.
- Estruch R et al. (2013, republished 2018). Primary prevention of cardiovascular disease with a Mediterranean diet supplemented with extra-virgin olive oil or nuts. New England Journal of Medicine, 378, e34.
- Holt-Lunstad J et al. (2015). Loneliness and social isolation as risk factors for mortality. PLOS Medicine, 12(2), e1001707.
- Laukkanen T et al. (2018). Sauna bathing is inversely associated with dementia and Alzheimer's disease in middle-aged Finnish men. Age and Ageing, 46(2), 245–249.
- Harrison DE et al. (2009). Rapamycin fed late in life extends lifespan in genetically heterogeneous mice. Nature, 460, 392–395.
- Brenner C (2023). NAD+ intermediates: the biology and therapeutic potential of NMN and NR. Nature Metabolism (review).
- Barbi E et al. (2018). The plateau of human mortality: demography of longevity pioneers. Science, 360(6396), 1459–1461.
- Livingston G et al. (2024). Dementia prevention, intervention, and care. The Lancet Commission update.
- NIA Interventions Testing Program. https://www.nia.nih.gov/research/dab/interventions-testing-program-itp
- Global BMI Mortality Collaboration (2016). Body-mass index and all-cause mortality. The Lancet, 388(10046), 776–786.
Read next:
Follow new articles
Add SciHub101 to your feed reader to see new science and technology stories.
About the Author
SciHub101 is an independent science and technology publication founded and edited by Buğra Sözeri, a software engineer and app developer based in Türkiye. AI tools assist with drafting and research. Source documentation in the existing archive is uneven, and articles are being reviewed and corrected. The Editorial Team byline identifies editorial responsibility; it does not certify specialist or independent human review. Where we compare products, anything built by our own team is labelled as such — see the editorial guidelines and About page for how corrections and disclosures work.
Related Articles
Cardiovascular Disease & Atherosclerosis: The Biology
How atherosclerosis causes heart attacks and strokes: plaque formation, LDL causality, inflammation, statins, PCSK9 drugs, and heart failure biology.
H5N1 Bird Flu Pandemic Risk: 2026 Update
Where H5N1 stands in October 2026: 72 U.S. human cases, dairy cattle spread, what would signal pandemic risk, and what CDC says about milk and vaccines.
The 12 Hallmarks of Aging Explained (2026): Science, Mechanisms, and Interventions
The 12 hallmarks of aging from López-Otín's 2023 Cell update, sorted by tier, with the human trial evidence for rapamycin, senolytics, and NAD+ precursors.
Why We Age — The Biology of Getting Old
The 12 hallmarks of aging, why evolution allowed us to grow old, and what interventions — from rapamycin to reprogramming — actually have evidence.
Why Aging Is a Disease — And Could We Actually Cure It?
For most of history, aging was accepted as inevitable. A growing group of scientists now argue it's a biological process that can be understood, slowed, and perhaps reversed. Here's where the science actually stands.
Countries with the Highest Life Expectancy (Ranked)
Japan's women live to an average of 87.7 years — the longest female life expectancy ever recorded for a large country. At the national level, Hong Kong leads all territories at 85.5 years, while Japan tops sovereign nations at 84.7. This is a story of diet, healthcare, culture, and the biology of longevity.